IFNA1 and melanoma: Hamid and colleagues [53] investigated an 18-gene T-cell inflamed GEP, which consisted of IFN-responsive genes and was developed in a previous study with 81 melanoma patients treated with pembrolizumab [61] in a large phase Ib clinical trial (N = 655).